Georg H.
- Country
- Germany
- Department
- Schwerpunktpraxis der Gynäkologie und Onkologie
Research Overview
- CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS
- Phase III Randomized, Double-Blind Trial of Atezolizumab with Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
- Evaluation of Elacestrant and Olaparib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer with gBRCA1/2 Mutations
Data & Insights
Has run more than one trial at 148 of 469 partner sites.
Specializations
Early Stage Breast Cancer
The investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative early breast cancer, with particular emphasis on developing personalized therapeutic approaches for patients with varying risk levels.
- Node-positive breast cancer management
- Endocrine therapy optimization
- Risk-stratified treatment approaches
Their work extends to evaluating novel therapeutic combinations for improved patient outcomes in early-stage disease.
Advanced Breast Cancer
Focus areas include the treatment of locally advanced and metastatic breast cancer, particularly in patients with specific genetic mutations such as gBRCA1/2.
- Targeted therapy development
- Novel drug combinations
- Resistance pattern analysis
The investigator studies comprehensive treatment strategies for advanced disease states, including molecular pattern analysis.
Triple-Negative Breast Cancer
Research interests include innovative therapeutic approaches for triple-negative breast cancer, incorporating both traditional chemotherapy and immunotherapy strategies.
- Neoadjuvant treatment protocols
- Immunotherapy integration
- Treatment response assessment
Their work encompasses both neoadjuvant and adjuvant treatment phases in triple-negative disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.